Weekly Recap: Navtemadlin for myelofibrosis and potravitug for BK virus
Ipsen SA (EURONEXT:IPN) is expanding its oncology and rare-disease pipeline with buys of Kartos (navtemadlin) and Memo Therapeutics (potravitug) totaling up to ≈€2.6bn in milestones, while managing share buybacks and an arbitration with Galderma amid investor concerns over rising deal costs in Chin…